Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 71 to 80 of 545 total matches.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
,
more than in any previous year.1 Several guidelines on
the management of opioid use disorder ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
impairment
Zubsolv 5.7/1.4 mg produces
systemic buprenorphine levels
equivalent to those seen with
8 mg ...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 doi:10.58347/tml.2023.1684b | Show Introduction Hide Introduction
Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
mutations
(16.6 vs 10.9 months).1
ADVERSE EFFECTS — The adverse effects of niraparib/abiraterone acetate ...
Akeega (Janssen), a fixed-dose combination of
the oral poly(ADP-ribose) polymerase (PARP)
inhibitor niraparib (Zejula) and the antiandrogen
abiraterone acetate (Zytiga, and others), has been
approved by the FDA for use in combination with
prednisone for treatment of adults with deleterious
or suspected deleterious BRCA-mutated (BRCAm)
metastatic castration-resistant prostate cancer
(mCRPC). Niraparib has been available since 2017
for treatment of epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Abiraterone acetate has
been available since 2011 for treatment of CRPC...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e146-7 doi:10.58347/tml.2023.1684c | Show Introduction Hide Introduction
In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
duration of
response was 14 months.1 ADVERSE EFFECTS — In the FOCUS trial, cytopenias,
fatigue, nausea ...
...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e148 doi:10.58347/tml.2023.1684d | Show Introduction Hide Introduction
Talquetamab (Talvey) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
(MonumenTAL-1;
summarized in the package insert) that included
232 patients who received ≥4 prior systemic ...
Talquetamab-tgvs (Talvey – Janssen), a bispecific
GPRC5D-directed T-cell engager, has been granted
accelerated approval by the FDA for treatment of
relapsed or refractory multiple myeloma in adults
who received ≥4 prior lines of therapy, including a
proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Accelerated
approval was based on the response rate and
durability of response. Talquetamab is the first
bispecific GPRC5D-directed T-cell engager to be
approved in the US
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e149-50 doi:10.58347/tml.2023.1684e | Show Introduction Hide Introduction
Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
-approval for the
same indication.1-3
from baseline at 18 months in the CDR-SB score
was +1 ...
Lecanemab-irmb (Leqembi – Eisai/Biogen), the IV
amyloid-directed monoclonal antibody that received
accelerated approval from the FDA in January 2023
for treatment of early Alzheimer's disease, has now
received full approval from the FDA based on a trial
showing that it slowed cognitive and functional decline
in patients with mild cognitive impairment (MCI) or
mild Alzheimer's disease dementia and confirmed
presence of brain amyloid. The IV amyloid-directed
monoclonal antibody aducanumab (Aduhelm) has
received only an accelerated FDA-approval for the
same indication.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):129-30 doi:10.58347/tml.2023.1683a | Show Introduction Hide Introduction
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
in the US for this indication
(see Table 4).1
SGLT2 INHIBITORS — SGLT2 inhibitors decrease renal
glucose reabsorption ...
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth SGLT2
inhibitor to be approved in the US for this indication
(see Table 4).
Med Lett Drugs Ther. 2023 Aug 21;65(1683):130-2 doi:10.58347/tml.2023.1683b | Show Introduction Hide Introduction
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
monthly, was the first.1
Buprenorphine is also available for treatment of
opioid use disorder ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Linaclotide (Linzess) for Functional Constipation
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
idiopathic
constipation and irritable bowel syndrome with
constipation in adults.1 The drug has now ...
The guanylate cyclase-C receptor agonist linaclotide
(Linzess – Abbvie/Ironwood) was first approved by
the FDA in 2012 for treatment of chronic idiopathic
constipation and irritable bowel syndrome with
constipation in adults. The drug has now been
approved for treatment of functional constipation in
patients 6-17 years old. Linaclotide is the only drug
to be approved in the US for treatment of functional
constipation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):135-6 doi:10.58347/tml.2023.1683d | Show Introduction Hide Introduction
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
has been available
since 2000 for this indication. The injectable
glucagon-like peptide-1 (GLP-1) receptor agonists ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor empagliflozin has been available for years
alone (Jardiance – Boehringer Ingelheim) and in
combination with metformin (Synjardy) to improve
glycemic control in adults with type 2 diabetes. Both
products have now been approved for use in children
≥10 years old. Empagliflozin is the second oral drug
to become available in the US for treatment of type
2 diabetes in children; metformin has been available
since 2000 for this indication. The injectable
glucagon-like peptide-1 (GLP-1) receptor agonists
liraglutide (Victoza) and...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e137 doi:10.58347/tml.2023.1683e | Show Introduction Hide Introduction